Panomics in the News

Proteomics in Multiplex
Panomics of Redwood City, California, expands its range of chemiluminescence-based Protein-Domain Arrays with the addition of WW and SH2 domains.
Nature, vol. 429, May 6, 2004

Probing the Proteome
Panomics of Redwood City, California, produces Human Cytokine Antibody Array 2.0 for profiling the expression of 21 well-studied human cytokines.
Nature, vol. 424, Jul. 31, 2003

Detecting Transcription Factor Interactions
Panomics' array-based kits map transcription factor networks.
The Scientist, Oct. 14, 2002

High-Throughput Gel Shifts
Panomics releases array-based transcription factor profiling system.
The Scientist, Sept. 17, 2001

Press Releases

December 11, 2007
Panomics Wins Frost & Sullivan Entrepreneurial Company of the Year Award for 2007 PDF

April 25, 2007
SH2Plex

April 25, 2006
Panomics Announces Formation of New European Subsidiary.

February 10, 2006
Genospectra Announces The Acquisition Of Panomics, A Leading Reagents Provider

February 10, 2006
Sigma-Aldrich Strengthens Position In Rnai And Cell-Based Assays Through Licensing And Equity Position In Genospectra

October, 2005
Panomics introduces the Methylation Promoter PCR Kit for quick and easy detection of methylation status of promoter of interest.

October, 2005
Panomics releases NFκB Reporter 293, NIH3T3, and C2C12 Reporter Stable Cell Lines for high-throughput analysis of NFκB activation.

September 7, 2005
Genospectra Appoints George E. Bers Executive Vice President, Commercial Operations

September, 2005
Panomics introduces mammalian expression vectors for 74 kinases.

July 19, 2005
Genospectra Signs Exclusive License and Multiyear Collaboration Agreement With CNRS

July, August, 2005
Panomics introduces 9 new Assay Kits to quantify activation ofHIF, ER, AP-1, p53, GR, Stat-1, MEF-2, Sp1, and GATA-1.

June, 2005
Panomics introduces the Methylation Promoter Array for high throughput analysis of promoter methylation.

June 9, 2005
Genospectra Introduces QuantiGene Plex

June, 2005
Panomics introduces Western Breast and Lung Cancer Blots to assess specific protein expression among human breast & lung cancer tissues.

May 25, 2005
Genospectra Introduces EXPRESS-si Delivery Reagent

May, 2005
Panomics introduces the NFκB Assay Kit to quantify activation of NFkB p50.

May, 2005
Panomics introduces the Phosphotyrosine Profiling Array to profile multiple interacting partners of tyrosine phosphorylated proteins.

May, 2005
Panomics introduces EGFR, PDGFR, IGF-IR Tyrosine Phosphorylation Arrays to profile multiple interacting partners of activated EGFR, PDGFR, and IGF-IR proteins.

May, 2005
Panomics releases SRF Reporter HeLa Stable Cell Line for high-throughput analysis of AP-1 activation.

April, 2005
Panomics releases AP-1 Reporter 293 Stable Cell Line for high-throughput analysis of AP-1 activation.

March, 2005
Panomics releases CREB Reporter 293 & CHO Stable Cell Lines for high-throughput analysis of CREB activation.

February, 2005
Panomics releases in vivo Kinase Assay Kit to monitor specific kinase activity.

January, 2005
Panomics releases NFκB Reporter 293T and A549 Stable Cell Lines for high-throughput analysis of NFkB activation.

January, 2005
Panomics releases Stat3 and Stat1 Reporter HeLa Stable Cell Lines for high-throughput analysis of in vivo drug efficacy and specificity.

January 18, 2005
Panomics releases NFAT Reporter Stable Cell Line for high-throughput analysis of NFAT activation.

December, 2004
Panomics introduces the Mouse shRNA Vector Mixes to complement its wide array of shRNA Vectors (125 now available).

November, 2004
Panomics introduces two more versions of the popular Transcription Reporter Array for simultaneously monitoring the activation of multiple transcription factors in vivo.

October 19, 2004
Genospectra Announces Novel State-Responsive Dye License

October 26, 2004
Panomics introduces the the shRNA Western Blots to provide a quick and simple means to determine which transcription factors (TF) could be driving the expression of a specific protein. They are carefully optimized to reduce TF expression by as much as 80-90%.

October 19, 2004
Panomics, Inc. Panomics introduces the NFκB Reporter Stable Cell Line for high-throughput analysis of NFkB activation.

October, 2004
Panomics, Inc. was selected as one of the Top 100 Fastest Growing Private Companies in the Bay Area by the San Francisco Business Times, and ranked Number 4. This prestigious ranking was published in a special Top 100 Edition in the October 8 issue of this business journal.

September 28, 2004
Panomics, Inc. introduces Protein/DNA Array Combo Array, further expanding the highly popular Protein/DNA Arrays line. This array enables the user to profile the activity of 345 transcription factors in one single hybridization experiment!

September 21, 2004
Panomics, Inc. introduces SNPCapture’ Transcription Factor Mutations ELISA Kits to detect mutations in a wide range of transcription factors using PCR amplification and specially designed primers. These easy-to-use kits employ a novel technology in a high-throughput ELISA platform. No capital equipment is required, nor is gel electrophoresis involved.

September, 2004
Panomics, Inc. introduces SNPCapture’ Cytokine Mutations ELISA Kits to detect mutations in a wide range of cytokine genes using PCR amplification and specially designed primers. These easy-to-use kits employ a novel technology in a high-throughput ELISA platform. No capital equipment is required, nor is gel electrophoresis involved.

July 22, 2004
Dharmacon and Genospectra to Launch Genome-Wide Line Of Novel RNA Assays forGene Silencing Measurement

June 28, 2004
Panomics, Inc. introduces SNPCapture’ Cystic Fibrosis Mutation Screening Kit to detect mutations across all 27 exons of the human CF gene. This easy-to-use kits employs a novel technology in a high-throughput ELISA platform. No capital equipment is required, nor is gel electrophoresis involved.

May 4, 2004
Panomics introduces the Reporter Vectors to report the binding activity of a single transcription factor. The Reporter Vectors provide a simple, straightforward and effective means of measuring promoter response in cells.

April 13, 2004
Panomics, Inc. introduces Protein/DNA Array Version III, further expanding the highly popular Protein/DNA Arrays line. These arrays provide a unique tool for high-throughput functional analysis of eukaryotic transcription factors (TFs).

March 31, 2004
Panomics introduces 39 NEW siRNA Vectors. These transfection-ready constructs are functionally tested and reduce transcription factor (TF) gene expression by more than 80%. We now offer siRNA vectors for CBP, c-myc, p300, PPAR gamma, Stat5, c-Src, and more. To view the complete list of siRNAs now available.

March 16, 2004
Panomics, Inc. introduces SNPCapture’ p53 Mutation Screening Kit to detect mutations in the DNA-binding region of p53. This easy-to-use kit employs a novel technology in a high-throughput ELISA platform. No capital equipment is required, nor is gel electrophoresis involved.

March 9, 2004
Panomics, Inc. introduces the SRC1-TF Interaction Arrays to determine how the transcriptional coactivator steroid receptor activator 1 (SRC1) interacts with multiple TFs—all in a single assay. Unlike traditional methods, this array-based technique generates a global view of SRC1-protein interactions.

February 11, 2004
Panomics, Inc. introduces the Mouse Angiogenesis Domain Array expanding on the popular Human Angiogenesis Array for profiling expression at the protein level. This array facilitates the detection of multiple angiogenesis-specific cytokines from biological sources, such as cell extracts, tissue lysates, conditioned media, patient sera, and plasma.

January 27,2004
Panomics introduces 46 NEW siRNA Vectors. These transfection-ready constructs are functionally tested and reduce transcription factor (TF) gene expression by more than 80%.Each siRNA consists of a mix of up to 3 plasmids that target one TF mRNA sequence. We currently offer siRNA vectors targeting a wide variety of TFs, such as: ATF1, CREB1, EGR, E2F1, Fos, GATA1, Jun, NFkBp50, NFkBp65, PPARA, PPARD, Sp1, Stat1, and YY1.To view the complete list of siRNAs.

January 20, 2004
Panomics, Inc. introduces the SH2 Domain Array for assessing interactions between a protein of interest and multiple SH2 domains. This rapid, economical method enables you to profile binding with up to 34 SH2 domains in one assay. Everything you need is provided in an easy-to-use kit format.

November 7, 2003
Panomics, Inc. introduces SNPCapture’ ELISA Mutation Detection Kits for genotyping. These easy-to-use kits employ a novel, patent pending technology in a high-throughput ELISA platform. No additional expensive equipment is required, nor is gel electrophoresis involved. Less post-PCR sample manipulation means less opportunity for cross-contamination. Best of all, the SNPCapture’ assay is 100% accurate.

November, 2003
Panomics, Inc. introduces the newest array for profiling cytokine expression at the protein level—the Mouse Cytokine Antibody Array 1.0. Like the other Cytokine Antibody Arrays, this new array can be used with samples from a variety of sources, including cell lysates, conditioned media, patient sera, plasma, and urine. A total of 18 mouse cytokine antibodies are immobilized on the Mouse Cytokine Antibody Array 1.0 membrane.

November 7, 2003
Panomics, Inc. is pleased to announce the acquisition of FreshGene, Inc., a diagnostics company based in Concord, CA. FreshGene's mission has been to develop innovative technologies for SNP genotyping. One of these methods was further developed by Panomics to create the ELISA-based SNPCapture’ Mutation Detection Kits. Now, FreshGene and Panomics join forces to expand this product line and create exciting new technologies.

September 9, 2003
The new TF Protein Array represents a significant improvement over traditional methods like pull-down assays, co-immunoprecipitation, super-gel shift, and the yeast two-hybrid system. A single hybridization experiment reveals how a protein of interest interacts with 54 transcription factor proteins immobilized on an array membrane.

September 23, 2003
Panomics, Inc. introduces the WW Domain Array, a high-throughput tool for investigating protein binding to WW domains. The assay is straightforward: simply express a protein of interest in bacteria, then incubate the extract with the array membrane. Protein interactions literally take place on the membrane, upon which 67 WW domains have been immobilized so that they remain folded in active conformations. The signal can be visualized using chemiluminescent detection.

September 9, 2003
Panomics, Inc. introduces the p300-TF Interaction Array for profiling the signal-associated changes of p300 interactions. Unlike conventional methods, this new array can be used to determine how p300 interacts with multiple TFs in a single experiment.

August, 2003
The National Institutes of Health (NIH) has awarded Panomics, Inc. a fast-track SBIR grant (Small Business Innovation Research). The grant will be mainly devoted to establishing an interaction network of transcription factors in order to better understand the mechanism of transcription regulation.

July 23, 2003
The Cardiac Marker Array profiles the level of active cardiac marker proteins. Unlike traditional methods such as ELISA, which can only assess one cardiac marker at a time, the Cardiac Marker Array profiles the level of four active cardiac marker proteins in one assay.

July 23, 2003
The siRNA Vectors are designed to suppress transcription factor (TF) genes. These functionally tested vectors each contains a region encoding an RNA sequence that is post-transcriptionally converted into a siRNA-like transcript. The vector-expressed siRNA then targets a specific TF-encoding mRNA for degradation through the RNA interference mechanism. Simply transfect the vectors into your cells and you will have dramatically reduced TF activity.

June 10, 2003
The Rat Brain Northern Blots will enable you to determine the abundance of mRNA transcripts in the specific regions of the brain. The blots are ideally suited for neuroscience applications through their meticulous preparation and high quality mRNA.

February 18, 2003
The PDZ Domain Array lets you determine whether a protein of interest binds to human PDZ domains. Unlike traditional methods such as co-immunoprecipitation, the PDZ Domain Array facilitates assessment of binding to 28 PDZ domains in one hybridization. Moreover, this array-based assay identifies interactions between a ligand and PDZ domains that remain folded in active conformations.

February 4, 2003
Panomics, Inc. introduces Adiponectin ELISA Kits for detecting adiponectin in serum or plasma samples, adipocytes, or conditioned media. These kits facilitate high-throughput screening, allowing quantification of adiponectin levels in up to 96 samples at once.

January 27, 2003
The Transcription Reporter Array is for simultaneously monitoring the activation of 24 transcription factors in vivo. Unlike transcription reporter vectors, which monitor a single TF at a time, this new array facilitates analysis of the activation of multiple transcription factors under different experimental conditions. The Transcription Reporter Array also enables the assessment of interpathway cross-talk, allowing users to tease apart multiple layers of regulation in a single step.

January 10, 2003
Panomics, Inc. introduces four ELISA tests for quantitative assessment of tumor marker concentration. These tests are designed for quick, efficient screening of multiple human serum samples for antigens that are elevated in different cancers. Panomics currently offers ELISA tests for Alpha-fetoprotein and three cancer antigens (CA125, CA15-3, and CA19-9).

January 15, 2003
A new line of arrays for profiling cytokine expression at the protein level, the Cytokine Antibody Arrays, facilitate the simultaneous detection of multiple cytokines from a variety of sources, including cell lysates, conditioned media, patient sera, plasma, and urine. These arrays have several advantages over conventional methods.

August 26, 2002
TF-TF Interaction Array II represents a significant improvement over co-immunoprecipitation and super-gel shift assays. In contrast to these time-consuming and inefficient assays, TF-TF Interaction Arrays allow assessment of interactions between multiple transcription factors (TFs)—in a single hybridization experiment.

August 1, 2002
With the SH3 Domain Array II, you can determine whether your protein of interest binds to 37 different SH3 domains—all in one experiment. The SH3 Domain Array I, which includes 38 different SH3 domains, is also available.

July 30, 2002
Genospectra Appoints Dr. Frank Witney Chief Executive Officer

June 19, 2002
Panomics, Inc. introduces the Protein/DNA Array II—the second edition of our array for high-throughput functional analysis of eukaryotic transcription factors (TFs). This new array represents a significant improvement over cumbersome gel mobility-shift assays, which only permit the characterization of one TF at a time. With the Protein/DNA Array II, the activities of 96 TFs can be characterized simultaneously.

April, 2002
The National Institutes of Health (NIH) has awarded Panomics, Inc. a Small Business Innovation Research (SBIR) grant. The grant will be devoted to the development of a rapid induction system for gene expression.

November, 2001
NIH awards Panomics, Inc. a Small Business Innovation Research (SBIR) grant. The grant will be devoted to the development of technologies for the identification of short-lived proteins.

October 29, 2001
Announcing the new SH3 Domain Array—the first array-based system to characterize protein function!

October 5, 2001
Alpha Innotech and Panomics Announce Strategic Alliance for Genetic Arrays

June 15, 2001
Panomics, Inc. introduces the new Protein/DNA Array for high-throughput functional analysis of eukaryotic transcription factors (TFs).

June 15, 2001
Panomics, Inc. introduces the new p53 Target Gene Array–designed specifically for profiling the expression pattern of genes that are induced by p53.